Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy
Crohn's & Colitis 360 · 01.07.2024 · 6 (3)
DOI: 10.1093/crocol/otae040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 20.08.2024. Verfasst von Corey A Siegel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Patients with Crohn’s disease (CD) or ulcerative colitis (UC) often cycle through conventional therapies (CT) with different mechanisms of action (MOA) before initiating advanced therapy (AT). We describe treatment patterns among patients with CD/UC.
Methods
Using Merative MarketScan Research databases, adult patients with CD/UC were identified from medical/pharmacy claims (2017–2021). Patients had ≥1 hospitalization or ≥2 outpatient visits (≥30 days apart within 1 year) for CD/UC. Two cohorts were established; cohort 1: Newly diagnosed patients (index date is the date of first diagnosis) and cohort 2: Patients initiating AT (index date is the date of first AT). First-line treatment patterns (cohort 1) and CT pathways before AT initiation (cohort 2) by the number of episodes (ie, adding a new therapy, switching to another therapy, or restarting the same therapy after ≥60 days) and MOA are reported.
Results
Among newly diagnosed patients in cohort 1 (CD: n = 1739; UC: n = 2740), 14.4% (CD) and 5.9% (UC) of patients had any AT use during the follow-up period (mean: 2.3 years; ≥ 77% initiated corticosteroids). Among patients in cohort 2 (CD: n = 2594; UC: n = 2431), the mean number of CT episodes before AT initiation was 4.0 ± 4.3 (CD) and 5.9 ± 5.0 (UC). Among those with ≥1 corticosteroid episode (CD: 82.2%; UC: 91.5%), the mean number of episodes was 4.6 ± 4.3 (CD) and 6.3 ± 5.0 (UC). Overall, 13.3% (CD) and 23.7% (UC) of patients cycled through 3 MOAs before AT initiation.
Conclusions
Despite treatment recommendations, few newly diagnosed CD/UC patients initiated AT as their first treatment. Moreover, patients cycled through multiple CTs before initiating AT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
- Department of Health Economics and Outcomes Research, AbbVie, Inc, North Chicago, IL, USA.
- Division of Gastroenterology, Department of Medicine, New York University Langone Medical Center, New York, NY, USA.
ORCID-Profile: Corey A Siegel
Förderung
- AbbVie
Zitieren
APA
Siegel, C. A., Sharma, D., Griffith, J., Doan, Q., Xuan, S., & Malter, L. (2024). Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy. Crohn's & Colitis 360, 6(3). https://doi.org/10.1093/crocol/otae040
Vancouver
Siegel CA, Sharma D, Griffith J, Doan Q, Xuan S, Malter L. Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy. Crohn's & Colitis 360. 2024;6(3). doi:10.1093/crocol/otae040
BibTeX
@article{Siegel2024,
author = {Siegel, Corey A and Sharma, Dolly and Griffith, Jenny and Doan, Quynhchau and Xuan, Si and Malter, Lisa},
title = {Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy},
journal = {Crohn's & Colitis 360},
year = {2024},
volume = {6},
number = {3},
doi = {10.1093/crocol/otae040}
}
EUVIMED